NASA Administrator Daniel Goldin Explains Timing, Purpose Of Big Changes At Agency

Editor's Note: Daniel Goldin, administrator of the National Aeronautics and Space Administration, was named to his $14 billion agency's top post seven months ago, having come from a position as vice president of TRW Inc.'s Space & Technology Group in Redondo Beach, Calif. In October, he initiated a series of major changes in the structure of NASA's space sciences research program. For example, Goldin has separated Mission to Planet Earth, the agency's Earth-observation satellite program, from t

Written byDaniel Goldin
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Editor's Note: Daniel Goldin, administrator of the National Aeronautics and Space Administration, was named to his $14 billion agency's top post seven months ago, having come from a position as vice president of TRW Inc.'s Space & Technology Group in Redondo Beach, Calif. In October, he initiated a series of major changes in the structure of NASA's space sciences research program. For example, Goldin has separated Mission to Planet Earth, the agency's Earth-observation satellite program, from the rest of the space sciences and created a separate division for this program that reports directly to him. He also has split life and microgravity sciences from other physical sciences and from exploration.

Also, Goldin has dismantled the Office of Space Science and Applications, where the bulk of NASA's science programs resided, and moved the highly regarded head of OSSA, Lennard Fisk, to a newly created position as chief scientist for NASA. This ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies